Thomas Verstraeten | Managing Director
P95 | Belgium

Thomas Verstraeten, Managing Director, P95

Thomas Verstraeten graduated as MD from Ghent University in 1987 and obtained a degree in Tropical Medicine from the Institute of Tropical Medicine in Antwerp in 1988. After about 10 years working in the field in emergency relief and HIV/STD research and surveillance in both Belgium and Africa, he went back to school to obtain a Masters in biostatistics from the University of Limburg in 1999. Following this, he was selected for a 2-year fellowship as Epidemiology Intelligence Service officer at the Centers for Disease Control where he was stationed within the Vaccine Safety Branch of the National Immunization Program. From 2001 to 2011, he has been employed by GlaxoSmithKline where he was first responsible for the vaccine epidemiology group, for another 5 years in charge of the company's vaccine safety group. In 2011 he founded P95, a private research company specialised in pharmacovigilance and infectious disease epidemiology. The P95 team of 15 epidemiologists, statiticians and analysts provide support to both public helath and industry partners.

Appearances:



DC Co-conference Day 2 April 4 @ 12:55

A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among the elderly

  • We searched the literature for clinical trials (CTs) including new adjuvant systems (AS01, AS02, AS03, or MF59), used in people of 50 years and older, published between January 1995 and September 2017.
  • 12 CTs were retained on AS01/AS02, AS03 and MF59 adjuvants, respectively, covering 92,123 subjects
  • This systematic literature review showed no overall increase in SAEs, fatalities, or unsolicited AEs following newly adjuvanted vaccines.
  • Higher rates for local or general AEs were observed for all newly adjuvanted vaccines, but AEs were mostly mild and transient.

back to speakers